Arbutus Biopharma Corp - Common Shares, without par value (ABUS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / Common Shares, without par value
Symbol
ABUS on Nasdaq
Shares outstanding
193,394,759
Price per share
$4.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
118,168,575
Total reported value
$536,370,600
% of total 13F portfolios
0%
Share change
+25,056
Value change
+$2,488,412
Number of holders
166
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 20% 0% $121,981,031 38,847,462 0% Roivant Sciences Ltd. 21 Feb 2025
MORGAN STANLEY 11% $67,587,436 21,524,661 Morgan Stanley 31 Dec 2024
Whitefort Capital Management, LP 7% $41,787,016 13,307,967 Whitefort Capital Master Fund, LP 20 Feb 2025
Two Seas Capital LP 5.4% $38,326,973 10,443,317 Two Seas Capital LP 30 Jun 2025

As of 30 Sep 2025, 166 institutional investors reported holding 118,168,575 shares of Arbutus Biopharma Corp - Common Shares, without par value (ABUS). This represents 61% of the company’s total 193,394,759 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MORGAN STANLEY 13% 24,450,612 +1.2% 0.01% $111,005,778
Whitefort Capital Management, LP 6.9% 13,343,228 0% 20% $60,578,255
BlackRock, Inc. 6.6% 12,677,496 -1.5% 0% $57,555,832
Two Seas Capital LP 5.7% 10,991,261 +5.2% 3% $49,900,325
VANGUARD GROUP INC 4.6% 8,991,082 -1% 0% $40,819,513
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.6% 5,014,941 +95% 0.04% $22,767,832
STATE STREET CORP 2.1% 4,098,318 -8.1% 0% $18,606,364
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,666,162 +0.8% 0% $16,647,559
ADAR1 Capital Management, LLC 1.5% 2,903,226 +2.7% 1.3% $13,180,646
GOLDMAN SACHS GROUP INC 1.1% 2,173,430 -29% 0% $9,867,372
Woodline Partners LP 1.1% 2,165,602 -13% 0.05% $9,831,833
BlackBarn Capital Partners LP 1% 2,000,000 -23% 3% $9,080,000
FOURSIXTHREE CAPITAL LP 1% 1,978,975 -23% 3.2% $8,984,547
Rubric Capital Management LP 0.81% 1,575,376 0% 0.1% $7,152,207
BANK OF AMERICA CORP /DE/ 0.75% 1,450,822 +21% 0% $6,586,732
OSAIC HOLDINGS, INC. 0.69% 1,338,503 -0% 0.01% $5,969,633
NORTHERN TRUST CORP 0.67% 1,289,413 +0.4% 0% $5,853,935
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.66% 1,274,833 +1.7% 0% $5,787,742
FourWorld Capital Management LLC 0.53% 1,020,910 -17% 11% $4,634,931
Rangeley Capital, LLC 0.43% 840,000 -2.9% 3.7% $3,813,600
Hudson Bay Capital Management LP 0.41% 800,000 -17% 0.02% $3,632,000
Aberdeen Group plc 0.41% 799,979 -19% 0.01% $3,631,905
UBS Group AG 0.4% 774,594 +307% 0% $3,516,657
BANK OF MONTREAL /CAN/ 0.4% 765,263 +27% 0% $3,474,294
Saba Capital Management, L.P. 0.35% 678,771 -46% 0.1% $3,081,620

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 52,138 $250,505 -$33,495 $4.81 3
2025 Q3 118,168,575 $536,370,600 +$2,488,412 $4.54 166
2025 Q2 118,112,086 $364,964,865 +$19,645,974 $3.09 162
2025 Q1 111,778,063 $390,115,649 +$29,488,807 $3.49 167
2024 Q4 104,090,922 $341,179,211 +$3,811,467 $3.27 153
2024 Q3 100,767,298 $387,947,597 +$15,539,741 $3.85 142
2024 Q2 96,359,001 $297,319,335 +$40,873,904 $3.09 128
2024 Q1 83,042,461 $214,259,487 +$6,782,119 $2.58 118
2023 Q4 334,729 $836,823 -$206,695 $2.50 2
2023 Q3 70,786,275 $143,703,155 +$8,047,661 $2.03 94
2023 Q2 66,185,012 $152,291,899 +$7,395,013 $2.30 107
2023 Q1 61,997,349 $187,829,702 +$26,480,057 $3.03 116
2022 Q4 53,716,878 $125,192,490 +$17,710,289 $2.33 106
2022 Q3 46,324,583 $88,579,063 +$2,665,975 $1.91 115
2022 Q2 43,881,530 $118,872,038 +$1,775,070 $2.71 97
2022 Q1 43,768,643 $130,256,900 +$4,148,714 $2.98 106
2021 Q4 38,926,412 $151,419,225 +$14,596,230 $3.89 111
2021 Q3 34,885,969 $149,676,117 +$25,429,404 $4.29 96
2021 Q2 28,888,149 $87,572,504 +$8,186,859 $3.03 82
2021 Q1 25,962,454 $86,372,263 +$11,913,177 $3.33 87
2020 Q4 21,883,583 $77,699,000 -$4,917,176 $3.55 70
2020 Q3 21,894,161 $68,491,000 +$7,507,561 $3.13 56
2020 Q2 26,121,391 $47,559,011 +$964,369 $1.82 45
2020 Q1 23,647,115 $23,876,071 -$13,526,378 $1.01 38
2019 Q4 24,017,014 $66,765,195 +$11,784,037 $2.78 47
2019 Q3 17,634,898 $26,893,042 -$3,348,567 $1.53 41
2019 Q2 21,111,841 $43,978,449 -$10,472,005 $2.08 53
2019 Q1 24,074,298 $86,183,302 -$441,990 $3.58 63
2018 Q4 24,134,988 $92,431,000 -$11,056,767 $3.83 62
2018 Q3 23,995,285 $227,114,146 +$17,699,387 $9.45 83
2018 Q2 20,414,032 $149,020,146 +$30,054,118 $7.30 64
2018 Q1 18,376,562 $91,884,575 -$79,595,847 $5.00 43
2017 Q4 34,210,365 $172,774,951 +$4,991,114 $5.05 48
2017 Q3 31,070,051 $192,640,124 -$1,099,180 $6.20 48
2017 Q2 36,886,584 $132,788,072 +$3,191,052 $3.60 43
2017 Q1 31,012,787 $100,791,065 +$962,388 $3.25 46
2016 Q4 35,912,876 $88,161,049 +$3,846,158 $2.45 51
2016 Q3 33,443,140 $115,042,069 +$54,656,797 $3.44 46
2016 Q2 17,373,536 $60,457,070 -$709,871 $3.48 46
2016 Q1 17,535,748 $72,418,000 -$3,356,385 $4.13 45
2015 Q4 18,357,298 $81,688,000 -$100,415,465 $4.45 46
2015 Q3 34,851,773 $212,246,000 +$210,982,968 $6.09 51
2015 Q2 207,417 $2,460,000 +$2,460,007 $11.86 1